Kroger Q4 2025 Earnings Release March 5, 2026 1 Safe Harbor This presentation includes certain statements that constitute "forward-looking statements" about Kroger's financial position and expected performance. These statements are based on management's assumptions and beliefs in light of currently available information. Such statements are indicated by words or phrases such as "committed," "could," "delivering," "guidance," "may," "model," "opportunities," "thesis," and other similar statements. Various un ...

Yixin Group (SEHK:02858) H2 2025 Earnings call March 05, 2026 06:00 AM ET Company ParticipantsMaggie Huang - AssociateXiaoguang Yang - CFOXuan Zhang - Chairman and CEOZhi Gao - Co-PresidentZhifeng Jia - CTOConference Call ParticipantsJennifer Wu - Equity Research AnalystLucia Zhang - Equity Research Analyst - Technology and ConsumerOperatorGood evening, investors and analysts. Welcome to the Yixin Group 2025 Annual Results Announcement. Today's session is being conducted by a live audio webcast and conferen ...

Yixin Group (SEHK:02858) H2 2025 Earnings call March 05, 2026 06:00 AM ET Company ParticipantsMaggie Huang - AssociateXiaoguang Yang - CFOXuan Zhang - Chairman and CEOZhi Gao - Co-PresidentZhifeng Jia - CTOConference Call ParticipantsJennifer Wu - Equity Research AnalystLucia Zhang - Equity Research Analyst - Technology and ConsumerOperatorGood evening, investors and analysts. Welcome to the Yixin Group 2025 annual results announcement. Today's session is being conducted by a live audio webcast and conferen ...

Investor Presentation March 2026 Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "confident," "potential," "continue," or other similar expressions. Among other things, quotations from mana ...

The following document has been prepared by JD.com, Inc. ("JD" or the "Company") solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or be relied on in connection with, any contract or investment decision ...

Yixin Group (SEHK:02858) H2 2025 Earnings call March 05, 2026 06:00 AM ET Speaker0Good evening, investors and analysts. Welcome to the Yixin Group 2025 annual results announcement. Today's session is being conducted by a live audio webcast and conference call. Please allow me to introduce the members of our management team joining us today. They are Chairman and CEO, Mr. Zhang Xu 安. Co-president, Mr. Gao Zhi. Chief Financial Officer, Mr. Yang Xiaoguang. Chief Technology Officer, Mr. Jia Zhifeng. Today's mee ...

Developing next generation antibodies into transformative cancer therapies that improve patients' lives Corporate Presentation Nasdaq: CMPX March 2026 DISCLAIMER This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after ...

Ultra-Rapid, Durable Remission in TRD with Minimal Clinic Burden GH Research PLC (Nasdaq: GHRS) March 2026 2026© GH Research PLC 1 Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC ("GH Research"). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or adviser of GH Research. This presentation does not purport to be all-inclusive ...

Financial Data and Key Metrics Changes - In 2025, the company's revenue reached RMB 73.4 billion, representing a year-over-year increase of 26.3% [7][18] - Non-IFRS profit totaled RMB 6.5 billion, up 36.3% year-over-year, with a non-IFRS profit margin of 8.9% [8][25] - The fourth quarter revenue was RMB 21 billion, reflecting a year-over-year increase of 27.4% [7][18] Business Line Data and Key Metrics Changes - Direct sales revenue reached RMB 16.9 billion in 2025, a year-over-year increase of 24.8%, accounting for 82.9% of total revenue [19] - Service revenue was RMB 12.6 billion, up 34.1% year-over-year, representing 17.1% of total revenue [19] - The company introduced over 100 new drugs during the year, a significant increase from 30 in 2024 [8] Market Data and Key Metrics Changes - The annual active user accounts reached approximately 200 million, with an addition of 34 million compared to the previous year [18] - The company established more than 300 self-operated pharmacies nationwide, integrating them with on-demand retail services [12] Company Strategy and Development Direction - The company aims to deepen its presence across key healthcare segments through an omnichannel approach and AI-powered healthcare services [6] - Future growth will focus on expanding partnerships with pharmaceutical companies and enhancing the user experience through innovative health solutions [9][15] - The company plans to leverage its supply chain strengths and direct sales capabilities to maintain leadership in the healthcare retail market [15][26] Management's Comments on Operating Environment and Future Outlook - The management expressed confidence in the company's growth potential, citing a large market size of RMB 3 trillion-4 trillion for the pharmaceutical sector [30] - The company is committed to enhancing user experiences and improving cost efficiency through AI-powered health service scenarios [26] - Management acknowledged the competitive landscape but emphasized the company's strengths in supply chain management and product quality [42] Other Important Information - The company has invested in AI technologies, with Dr. Dawei completing hundreds of millions of user interactions and achieving a 98% satisfaction rate [21][37] - The fulfillment expense ratio was 10.4%, and the selling and marketing expense ratio remained stable at 5.2% [23] Q&A Session Summary Question: Near term and three-year middle term prospects - Management highlighted the growth potential in the pharmaceutical sector and the importance of expanding product offerings and partnerships [29][34] Question: Competition landscape - Management expressed confidence in standing out among competitors due to strong supply chain management and product quality [42] Question: Plans for brick-and-mortar stores and M&A - Management clarified that there are no plans for large-scale M&A and emphasized a cautious approach to offline practices [48][52] Question: Progress of AI applications - Management discussed the positive outcomes from AI technologies and the potential for future commercialization [56][60]

Financial Data and Key Metrics Changes - In 2025, the company's revenue reached RMB 73.4 billion, representing a year-over-year increase of 26.3% [7][18] - Non-IFRS profit totaled RMB 6.5 billion, up 36.3% year-over-year, with a non-IFRS profit margin of 8.9% [8][25] - The fourth quarter revenue was RMB 21 billion, reflecting a year-over-year increase of 27.4% [7][18] Business Line Data and Key Metrics Changes - Direct sales revenue reached RMB 16.9 billion in 2025, up 24.8% year-over-year, accounting for 82.9% of total revenue [19] - Service revenue increased to RMB 12.6 billion, up 34.1% year-over-year, representing 17.1% of total revenue [19] - The company introduced over 100 new drugs in 2025, a significant increase from 13 in 2024 [8] Market Data and Key Metrics Changes - The annual active user accounts reached approximately 220 million, with an addition of 34 million compared to the previous year [18] - The company established over 300 self-operated pharmacies nationwide, integrating them with on-demand retail services [12] Company Strategy and Development Direction - The company aims to deepen its presence in key healthcare segments through an omnichannel approach and AI-powered healthcare services [6] - Future growth will focus on expanding partnerships with pharmaceutical companies and enhancing the user experience through innovative health solutions [9][15] - The company plans to leverage its supply chain strengths and direct sales capabilities to maintain leadership in the healthcare retail market [15] Management Comments on Operating Environment and Future Outlook - The management expressed confidence in the company's growth potential, citing a large market size of RMB 3 trillion-4 trillion for the pharmaceutical sector [30] - The company is committed to enhancing user experiences and improving cost efficiency through AI technologies [26] - Management highlighted the importance of a steady and cautious approach to offline business expansion, emphasizing the integration of AI in healthcare services [49] Other Important Information - The company achieved a growth margin of 24.8% in 2025, up 1.9 percentage points year-over-year [22] - The fulfillment expense ratio was 10.4%, and the selling and marketing expense ratio remained flat at 5.2% [23] - Cash flow from operating activities reached RMB 10.2 billion for the full year [25] Q&A Session Summary Question: Near term and three-year middle term prospects - Management indicated that the pharmaceutical sector, health products, and medical devices present significant growth opportunities, with plans to deepen engagement with pharmaceutical companies and enhance product offerings [29][30][34] Question: Competition landscape - Management expressed confidence in the company's ability to stand out among competitors by leveraging supply chain management and maintaining high product quality [40][41] Question: Plans for brick-and-mortar stores and M&A - Management clarified that there are no plans for large-scale M&A but emphasized the importance of offline practices and the integration of pharmacies to enhance user experiences [43][44][46]